ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Phase 3

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Venetoclax
Drug: Bortezomib
Drug: Placebo for venetoclax
Drug: Dexamethasone

First Posted Date: 2016-04-29

Last Posted Date: 2023-08-22

Lead Sponsor: AbbVie

Target Recruit Count: 291

Registration Number: NCT02755597

Locations: 🇫🇷
CHU Limoges - Dupuytren 1 /ID# 149292, Limoges CEDEX 1, Franche-Comte, France
🇮🇹
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 148942, Ancona, Italy
🇦🇺
Box Hill Hospital /ID# 149112, Box Hill, Victoria, Australia

and more 94 locations

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

Completed

Conditions: Psoriatic Arthritis
Crohn's Disease
Ankylosing Spondylitis
Ulcerative Colitis
Rheumatoid Arthritis
Psoriasis

Interventions: Biological: Adalimumab
Behavioral: AbbVie Care 2.0

First Posted Date: 2016-04-26

Last Posted Date: 2019-11-06

Lead Sponsor: AbbVie

Target Recruit Count: 427

Registration Number: NCT02750800

Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Biological: Adalimumab

First Posted Date: 2016-04-15

Last Posted Date: 2019-08-09

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT02739828

Locations: 🇸🇪
Sodersjukhuset, Stockholm, Sweden
🇸🇪
Blekinge Hospital, Karlskrona, Sweden
🇸🇪
Hallands Hospital Halmstad, Halmstad, Sweden

and more 8 locations

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

Phase 3

Completed

Conditions: Hepatitis C Virus Infection
Human Immunodeficiency Virus Infection
Chronic Hepatitis C
Compensated Cirrhosis and Non-cirrhotics

Interventions: Drug: ABT-493 coformulated with ABT-530

First Posted Date: 2016-04-14

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 153

Registration Number: NCT02738138

Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

Completed

Conditions: Ulcerative Colitis (UC)

First Posted Date: 2016-04-14

Last Posted Date: 2024-12-31

Lead Sponsor: AbbVie

Target Recruit Count: 265

Registration Number: NCT02738125

Locations: 🇫🇷
CHU La Réunion - site St Denis - Félix-Guyon /ID# 151556, Saint-Denis, France
🇫🇷
Cabinet Medical /ID# 155460, BAIE Mahault, Guadeloupe, France
🇫🇷
CHU Toulouse - Hopital Purpan /ID# 167179, TOULOUSE Cedex 9, Haute-Garonne, France

and more 77 locations

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Paritaprevir/ritonavir/ombitasvir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2016-04-01

Last Posted Date: 2019-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 216

Registration Number: NCT02725866

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus
Hepatitis C Virus

Interventions: Drug: sofosbuvir (SOF)
Drug: ABT-493/ABT-530
Drug: ribavirin (RBV)

First Posted Date: 2016-03-30

Last Posted Date: 2021-07-16

Lead Sponsor: AbbVie

Target Recruit Count: 136

Registration Number: NCT02723084

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2016-03-28

Last Posted Date: 2023-06-07

Lead Sponsor: AbbVie

Target Recruit Count: 197

Registration Number: NCT02720523

Locations: 🇯🇵
Nagoya University Hospital /ID# 148005, Nagoya-shi, Aichi, Japan
🇯🇵
Hamanomachi Hospital /ID# 147991, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Sapporo City General Hospital /ID# 147968, Sapporo, Japan

and more 47 locations

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Phase 2

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: risankizumab
Drug: placebo for risankizumab

First Posted Date: 2016-03-25

Last Posted Date: 2019-05-30

Lead Sponsor: AbbVie

Target Recruit Count: 185

Registration Number: NCT02719171

A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece

Completed

Conditions: Moderate to Severe Plaque Psoriasis

First Posted Date: 2016-03-18

Last Posted Date: 2020-04-15

Lead Sponsor: AbbVie

Target Recruit Count: 273

Registration Number: NCT02713295

Locations: 🇬🇷
PP of Ekaterini Galaterou /ID# 149713, Athens, AGIA Paraskeui, Greece
🇬🇷
PP of Antonios Seretis /ID# 149714, Athens, Chalandri, Greece
🇬🇷
PP of Maria Loukatou /ID# 149706, Athens, Glyfada, Greece

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy